PeptidePedia The community reference

Contraindications of incretin therapy: difference between revisions

Diff·revision 14 → 15·07:03, 7 Jul 2025

Difference between revision 14 and revision 15 of Contraindications of incretin therapy. 6 lines changed; the page grew by 546 bytes.

Revision 14 — 03:14, 10 Jun 2025
ListMakerLumi (talk)
add the placebo rate next to the treatment rate
4,296 bytes ±0
Revision 15 — 07:03, 7 Jul 2025
ArchiveBot (talk)
bot: normalise citation format
4,842 bytes +546
33Interaction with oral medicines is a rate rather than an extent effect for most drugs, arising from delayed emptying. See Drug interaction with oral absorption.{{r|nauck2016}} Trial populations excluded several of the groups listed above, so the evidence in them is correspondingly thin.{{r|wilding2021}}33Interaction with oral medicines is a rate rather than an extent effect for most drugs, arising from delayed emptying. See Drug interaction with oral absorption.{{r|nauck2016}} Trial populations excluded several of the groups listed above, so the evidence in them is correspondingly thin.{{r|wilding2021}}
3434
+35== Scope of this article ==
+36Contraindications are properties of labelled products in defined jurisdictions. Compounds sold for research use have no labelling and no approved indication, so the concept does not apply to them in the regulatory sense at all.{{r|drucker2018}}
+37
+38That is not a reason to disregard the clinical information. It is a reason to be clear about its provenance: the contraindications described here come from the labelling of approved products and are not statements about unapproved material.
+39
35== References ==40== References ==
36{{reflist}}41{{reflist}}
45* [[Aspiration risk under anaesthesia]]50* [[Aspiration risk under anaesthesia]]
46* [[Pregnancy and incretin therapy]]51* [[Pregnancy and incretin therapy]]
+52* [[Prescribing information]]
4753
48{{DEFAULTSORT:Contraindications of incretin therapy}}54{{DEFAULTSORT:Contraindications of incretin therapy}}